Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Clinical trial NCT02254031 · TERMINATED

Trial details

NCT number: NCT02254031
Sponsor: Boehringer Ingelheim
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2003-07-01
Primary completion: 2005-01-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.